Shareholders of the drugmaker Perrigo have shut the door on a $26-billion hostile takeover bid from Mylan. Mylan said that its cash-and-stock offer failed to garner enough interest from Perrigo shareholders by a Friday morning deadline to complete the deal. The generic drugmaker said about 40 percent of Perrigo shares had been tendered into the offer when it required more than 50 percent as a condition for the deal to go through. Perrigo shares...
↧